Ideaya Biosciences, Inc. (IDYA)

Key figures

The last twelve months reported, with the latest price and balance sheet.

Market value

$3.3B

Cash

$272.6M

Debt

$0

Debt to equity

0.00

Shares outstanding

96.4M

Financial statements

Revenue, profit and cash flow by fiscal year, each year linked to its annual report.

By quarter

What the company said with its results

From the second quarter 2026 results, filed 4 August 2026.

• Net loss widened to $112.5 million. The net loss was $112.5 million, against $98.5 million in the prior quarter. Net loss per share, basic and diluted, was $(1.22) versus $(1.11).
• Collaboration revenue rose on Servier reimbursements. Collaboration revenue was $8.9 million, from research and development services recognized over time under the Servier license for darovasertib.
• Operating loss widened on higher R&D. Loss from operations was $122.3 million, against $108.5 million in the prior quarter. Interest and other income, net, was $9.8 million.
• OptimUM-02 met its primary endpoint. In first-line HLA*A2:01-negative metastatic uveal melanoma, median PFS by blinded independent central review was 6.9 months with the combination versus 3.1 months in the ICT arm.
• Investigator-assessed PFS also improved. Investigator-assessed median PFS was 6.7 months with the combination versus 2.7 months in the ICT arm, with hazard ratio 0.36. Management described the safety profile as generally well-tolerated.
• Overall survival data still immature. Overall survival data were immature at the January 23, 2026 cutoff. Management noted an early trend in OS improvement with the combination.
• Full primary data shown at ASCO. Complete primary-analysis data from 313 patients were presented as a late-breaking oral at the 2026 ASCO meeting in Chicago.
• OptimUM-01 enrollment completed at about 100. Enrollment in the single-arm Phase 2 OptimUM-01 trial is complete at approximately 100 HLA*A2:01-positive patients. Data from about 85 efficacy-evaluable patients are planned for ESMO.
• OptimUM-11 Phase 3 trial initiated. With Servier, the company initiated a global Phase 3 trial, OptimUM-11, in the adjuvant setting of primary uveal melanoma, with about 450 patients and relapse-free survival as the primary endpoint.
• OptimUM-09 neoadjuvant update at ESMO. Updated clinical data from the ongoing Phase 2 OptimUM-09 trial of neoadjuvant darovasertib are planned for presentation at ESMO.
• IDE849 Phase 3 design under FDA discussion. Management is in discussions with the FDA on the design of a Phase 3 registrational trial of IDE849 in refractory SCLC and/or NEC, with more detail due with the second half data update.
• IDE849 Hengrui Phase 1 data at ESMO. The partner Hengrui's Phase 1 update in SCLC and NEC will include ORR, PFS, safety, and 12-month landmark OS from about 100 patients.
• IDE161 combination trial with IDE849. A Phase 1 combination trial pairs IDE849 with IDE161, a PARG inhibitor, in DLL3-upregulated solid tumors including SCLC, NEC and melanoma.
• IDE034 bispecific ADC in dose escalation. IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to internalize only when both targets are co-expressed on the same cell. A Phase 1 dose escalation trial is ongoing.

Company events

The newest 8-K filings of 105 held.

Every filing

The newest filings with the SEC of 192 held.

Insider trades

Form 4 trades by officers, directors and 10% owners, last 12 months.

Planned insider sales

Form 144 notices, filed when the sell order goes to the broker.

Large holders

Schedule 13D and 13G filings by holders of more than 5% of the voting shares.

Short interest

Shares sold short and not yet bought back, on each FINRA settlement date.

Funds that hold it

From each fund's latest Form 13F.

320 funds held it at 30 Jun 2026: 148 added and 86 trimmed in the quarter. The largest:

Peers

Companies in the same industry.

• Eli Lilly & Co. (LLY): revenue $79.7B, market value $1.21T
• Johnson & Johnson (JNJ): revenue $99.3B, market value $652.9B
• AbbVie Inc. (ABBV): revenue $64.4B, market value $506.1B
• Merck & Co., Inc. (MRK): revenue $66.6B, market value $348.1B
• Novartis AG (NVS): revenue $54.5B, market value $297.8B
• AstraZeneca PLC (AZN): revenue $58.7B, market value $263.1B
• Abbott Laboratories (ABT): revenue $46.6B, market value $177.7B
• Novo Nordisk A/S (NVO): revenue $46.8B, market value $171.0B
• Pfizer Inc. (PFE): revenue $63.7B, market value $168.0B
• Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $134.2B

What the company does

IDEAYA Biosciences is a precision medicine oncology company that discovers and develops cancer therapies. It works on small-molecule drugs and antibody-drug conjugates (ADCs) for solid tumors defined by their genetics. The company describes its clinical pipeline as nine potential first-in-class product candidates across four clinical focus areas.

The four focus areas

The first area is darovasertib for uveal melanoma. The second is ADC and DNA Damage Response (DDR) combinations.

The third area is the MTAP pathway, which targets tumors with MTAP gene deletions. The filing says these deletions occur in approximately 15% of all solid tumors. The programs here are IDE397, a MAT2A inhibitor, and IDE892, a PRMT5 inhibitor.

Darovasertib and uveal melanoma

Darovasertib is an oral small molecule inhibitor of protein kinase C (PKC) and the company's most advanced program. Approximately 95% of uveal melanoma patients carry activating mutations in GNAQ or GNA11. In metastatic disease, the company is testing darovasertib with Pfizer's crizotinib in OptimUM-02, a Phase 2/3 trial that has enrolled 437 patients. In primary disease, OptimUM-10 is a randomized Phase 3 neoadjuvant trial planned for approximately 450 patients.

The FDA has granted darovasertib Orphan Drug designation in uveal melanoma, Fast Track designation for the crizotinib combination in metastatic disease, and Breakthrough Therapy designation as a neoadjuvant treatment for primary disease. The company keeps all rights to darovasertib in the United States.

Partners and licences

Darovasertib is licensed from Novartis, with worldwide rights. In August 2025 the company granted Servier an exclusive licence to develop and commercialize it everywhere except the United States. Servier is responsible for regulatory and commercial work outside the United States, and the two companies share development costs. The filing lists royalties on those sales ranging from mid-teens to low-twenties percentages.

Pfizer supplies crizotinib for the darovasertib trials. Gilead supplies Trodelvy for trials combining it with IDE397 in urothelial cancer and non-small cell lung cancer, and each company keeps its own commercial rights. IDE161 is licensed from Cancer Research UK and the University of Manchester. IDE849 is licensed from Hengrui Pharma for all territories outside Greater China.

The Pol Theta (IDE705) and WRN (IDE275) programs transfer back to the company.

How it finds drugs

The company's discovery work combines small-molecule chemistry, structural biology and bioinformatics with biomarker work. Its INQUIRE chemical library covers over 200,000 chemical compounds. It also uses a machine-learning engine called HARMONY for molecular design.

The DECIPHER dual CRISPR library, built with the University of California, San Diego, allows evaluation of approximately 50,000 independent gene knockout combinations. A collaboration with the Broad Institute searches for synthetic lethality targets in ovarian cancer, and the company is a member of the Broad DepMap consortium. For patient selection, it has relationships with Foundation Medicine, Guardant Health and Tempus.

Manufacturing and selling

Contract manufacturers make the active ingredients and finished drugs for its small molecules, including STA Pharmaceutical, Yuhan Corporation, Patheon and Pharmaron. Biocytogen and Hengrui Pharma supply the in-licensed ADCs for development.

The company says it intends to become a fully integrated commercial stage biopharmaceutical company.

Competition and protection

The filing describes the industry as very competitive, with major pharmaceutical, specialty pharmaceutical and biotechnology companies in the field. In uveal melanoma, it names Immunocore's Kimmtrak as a commercialized therapy. For IDE849, it names Amgen's Imdelltra, a DLL3-directed therapy that received FDA accelerated approval.

As of 30 January 2026, the company owns or exclusively licenses patents and applications in approximately 71 distinct patent families. These include approximately 21 issued United States patents and 65 issued foreign patents.

Its people

The team is led by Chief Executive Officer Yujiro S Hata and includes cancer biologists, drug discovery chemists, translational biologists and drug development professionals. A scientific advisory board also guides the company.

*From IDEAYA Biosciences's annual report on Form 10-K for the year ended 31 December 2025. [The filing](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)*

From the company's 10-K.